The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwHRMM 2024 | Overcoming T-cell exhaustion to improve CAR-T efficacy in multiple myeloma
Roberto Mina, MD, University of Turin, Turin, Italy, comments on T-cell exhaustion, which limits the efficacy of CAR-T therapy in triple-class exposed patients with multiple myeloma. He highlights the lack of data but suggests using bispecific antibodies instead, as there is good data on the effectiveness of these agents. This discussion took place at the 1st International Workshop on High-Risk Multiple Myeloma (iwHRMM 2024), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
